- Home
- TLSI vs PZC Comparison
TLSI vs PZC Comparison
Compare TLSI & PZC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- PZC
- Stock Information
- Founded
- TLSI 2010
- PZC 2002
- Country
- TLSI United States
- PZC United States
- Employees
- TLSI N/A
- PZC N/A
- Industry
- TLSI Medical Specialities
- PZC Investment Managers
- Sector
- TLSI Health Care
- PZC Finance
- Exchange
- TLSI Nasdaq
- PZC Nasdaq
- Market Cap
- TLSI 204.0M
- PZC N/A
- IPO Year
- TLSI N/A
- PZC N/A
- Fundamental
- Price
- TLSI $4.89
- PZC $6.18
- Analyst Decision
- TLSI Strong Buy
- PZC
- Analyst Count
- TLSI 5
- PZC 0
- Target Price
- TLSI $10.90
- PZC N/A
- AVG Volume (30 Days)
- TLSI 154.7K
- PZC 48.2K
- Earning Date
- TLSI 08-13-2025
- PZC 01-01-0001
- Dividend Yield
- TLSI N/A
- PZC 4.68%
- EPS Growth
- TLSI N/A
- PZC N/A
- EPS
- TLSI N/A
- PZC N/A
- Revenue
- TLSI $32,141,000.00
- PZC N/A
- Revenue This Year
- TLSI $55.52
- PZC N/A
- Revenue Next Year
- TLSI $54.76
- PZC N/A
- P/E Ratio
- TLSI N/A
- PZC N/A
- Revenue Growth
- TLSI 46.20
- PZC N/A
- 52 Week Low
- TLSI $3.50
- PZC $6.30
- 52 Week High
- TLSI $6.04
- PZC $8.20
- Technical
- Relative Strength Index (RSI)
- TLSI 42.89
- PZC 42.67
- Support Level
- TLSI $4.85
- PZC $6.13
- Resistance Level
- TLSI $5.11
- PZC $6.25
- Average True Range (ATR)
- TLSI 0.30
- PZC 0.04
- MACD
- TLSI -0.03
- PZC 0.01
- Stochastic Oscillator
- TLSI 13.45
- PZC 31.75
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.